Distinguished in Ewing Sarcoma

Giovanni Grignani

Candiolo, IT 
Clinical Trials:Currently Recruiting for 3 Trials
Distinguished in Ewing Sarcoma
Candiolo, IT 
OverviewLocationsClinical Research

Overview

Giovanni Grignani practices in Candiolo, Italy. Mr. Grignani is rated as a Distinguished expert by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Solitary Fibrous Tumor, Osteosarcoma, Pancreaticoduodenectomy, and Hysterectomy.

His clinical research consists of co-authoring 185 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 7 articles and participated in 3 clinical trials in the study of Ewing Sarcoma.

Gender
Male

Locations

Candiolo, Italy
Other Locations
Perugia, 06123, Italy
Turin, Italy
Citta, Italy
Naples, 80126, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
Enrollment Status: Recruiting
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drug: INBRX-109
Study Phase: Phase 2
A Randomized Phase II Trial Comparing the Activity of trabectedIn vs Gemcitabine in Patients With Metastatic or Locally Advanced Leiomyosarcoma Pretreated With Conventional Chemotherapy
A Randomized Phase II Trial Comparing the Activity of trabectedIn vs Gemcitabine in Patients With Metastatic or Locally Advanced Leiomyosarcoma Pretreated With Conventional Chemotherapy
Enrollment Status: Recruiting
Publish Date: December 20, 2024
Intervention Type: Drug
Study Drugs: Trabectedin, Gemcitabine
Study Phase: Phase 2
Observational Study on Treatment of Skeletal Ewing Sarcoma at Diagnosis
Observational Study on Treatment of Skeletal Ewing Sarcoma at Diagnosis
Enrollment Status: Recruiting
Publish Date: December 20, 2024
Intervention Type: Other
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Nirogacestat Oral Tablet
Study Phase: Phase 3
Phase 2 Randomized Trial of Trabectedin + Olaparib vs. Trabectedin in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.
Phase 2 Randomized Trial of Trabectedin + Olaparib vs. Trabectedin in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.
Enrollment Status: Completed
Publish Date: December 04, 2024
Intervention Type: Drug
Study Drugs: Trabectedin, Olaparib
Study Phase: Phase 2
ERibulin in Advanced Solitary Fibrous Tumor, an ItaliaN Sarcoma Group Phase II Study (ERASING)
ERibulin in Advanced Solitary Fibrous Tumor, an ItaliaN Sarcoma Group Phase II Study (ERASING)
Enrollment Status: Completed
Publish Date: September 20, 2024
Intervention Type: Drug
Study Drug: Eribulin
Study Phase: Phase 2
ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma - Prospective Study (ISG/OS-2)
ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma - Prospective Study (ISG/OS-2)
Enrollment Status: Completed
Publish Date: May 20, 2024
Intervention Type: Other, Drug
Study Drug: Mifamurtide
Study Phase: Phase 2
Follow-up in Low Risk Gastrointestinal Stromal Tumors (GISTs) - Retrospective Analysis of Clinical Features and Outcomes
Follow-up in Low Risk Gastrointestinal Stromal Tumors (GISTs) - Retrospective Analysis of Clinical Features and Outcomes
Enrollment Status: Completed
Publish Date: February 01, 2024
Intervention Type: Other
Phase II, Single Arm, Non-randomized and Multicenter Clinical Trial of Regorafenib as a Single Agent in the First-line Setting for Patients With Metastatic and/or Unresectable KIT/PDGFR Wild Type GIST
Phase II, Single Arm, Non-randomized and Multicenter Clinical Trial of Regorafenib as a Single Agent in the First-line Setting for Patients With Metastatic and/or Unresectable KIT/PDGFR Wild Type GIST
Enrollment Status: Completed
Publish Date: March 27, 2023
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 2
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Enrollment Status: Completed
Publish Date: January 23, 2023
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2/Phase 3
Study With High Doses of Chemotherapy, Radiotherapy and Consolidation Therapy With Ciclofosfamide and Anticyclooxygenase 2, for the Metastatic Ewing Sarcoma
Study With High Doses of Chemotherapy, Radiotherapy and Consolidation Therapy With Ciclofosfamide and Anticyclooxygenase 2, for the Metastatic Ewing Sarcoma
Enrollment Status: Completed
Publish Date: September 19, 2022
Intervention Type: Drug
Study Drugs: TEMIRI, ADM, IFO, CYC, ETO, BUMEL, VIN
Study Phase: Phase 2
Phase III Study on Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma.
Phase III Study on Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma.
Enrollment Status: Completed
Publish Date: September 19, 2022
Intervention Type: Drug
Study Drugs: Standard Treatment (as per Protocol ISG SSG III), Intensified Chemotherapy
Study Phase: Phase 3
A Phase II Study on Trabectedin in Advanced Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma
A Phase II Study on Trabectedin in Advanced Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma
Enrollment Status: Completed
Publish Date: November 01, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase Ib Study on the Combination of Trabectedin and Olaparib in Unresectable Advanced/Metastatic Sarcomas After Failure of Standard Therapies
A Phase Ib Study on the Combination of Trabectedin and Olaparib in Unresectable Advanced/Metastatic Sarcomas After Failure of Standard Therapies
Enrollment Status: Completed
Publish Date: April 14, 2021
Intervention Type: Drug
Study Phase: Phase 1
Time to Secondary Resistance to Trabectedin After Interruption Versus Continuation in Responding Patients With Liposarcoma, Leiomyosarcoma and Synovial Sarcoma
Time to Secondary Resistance to Trabectedin After Interruption Versus Continuation in Responding Patients With Liposarcoma, Leiomyosarcoma and Synovial Sarcoma
Enrollment Status: Withdrawn
Publish Date: May 13, 2019
Intervention Type: Drug
Study Phase: Phase 3
Multicentric, Randomized Phase II Trial for the Treatment of Patients With Relapsed Osteosarcoma
Multicentric, Randomized Phase II Trial for the Treatment of Patients With Relapsed Osteosarcoma
Enrollment Status: Terminated
Publish Date: May 13, 2019
Intervention Type: Drug
Study Phase: Phase 2
Trabectedin in Soft Tissue Sarcomas. A Retrospective Observational Analysis (TrObs)
Trabectedin in Soft Tissue Sarcomas. A Retrospective Observational Analysis (TrObs)
Enrollment Status: Completed
Publish Date: May 10, 2019
Intervention Type: Drug
View 14 Less Clinical Trials

185 Total Publications

ASO Visual Abstract: Natural History of Primary Retroperitoneal Extra-Visceral Perivascular Epithelioid Cell Tumors (PECOMA): A Study from Transatlantic and Australasian Retroperitoneal Sarcoma Working Group (TARPSWG).
ASO Visual Abstract: Natural History of Primary Retroperitoneal Extra-Visceral Perivascular Epithelioid Cell Tumors (PECOMA): A Study from Transatlantic and Australasian Retroperitoneal Sarcoma Working Group (TARPSWG).
Journal: Annals of surgical oncology
Published: August 31, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Grignani's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 27 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile